关注
Rebekka Wegmann
Rebekka Wegmann
在 imsb.biol.ethz.ch 的电子邮件经过验证
标题
引用次数
引用次数
年份
Mapping human microbiome drug metabolism by gut bacteria and their genes
M Zimmermann, M Zimmermann-Kogadeeva, R Wegmann, AL Goodman
Nature 570 (7762), 462-467, 2019
8862019
Separating host and microbiome contributions to drug pharmacokinetics and toxicity
M Zimmermann, M Zimmermann-Kogadeeva, R Wegmann, AL Goodman
Science 363 (6427), eaat9931, 2019
3592019
The Tumor Profiler Study: integrated, multi-omic, functional tumor profiling for clinical decision support
A Irmisch, X Bonilla, S Chevrier, KV Lehmann, F Singer, NC Toussaint, ...
Cancer Cell 39 (3), 288-293, 2021
1032021
CellSIUS provides sensitive and specific detection of rare cell populations from complex single-cell RNA-seq data
R Wegmann, M Neri, S Schuierer, B Bilican, H Hartkopf, F Nigsch, F Mapa, ...
Genome biology 20, 1-21, 2019
492019
Ex vivo drug response heterogeneity reveals personalized therapeutic strategies for patients with multiple myeloma
K Kropivsek, P Kachel, S Goetze, R Wegmann, Y Festl, Y Severin, ...
Nature Cancer 4 (5), 734-753, 2023
182023
A functional analysis of 180 cancer cell lines reveals conserved intrinsic metabolic programs
S Cherkaoui, S Durot, J Bradley, S Critchlow, S Dubuis, MM Masiero, ...
Molecular Systems Biology 18 (11), e11033, 2022
182022
ROS induction targets persister cancer cells with low metabolic activity in NRAS-mutated melanoma
OM Eichhoff, CI Stoffel, J Käsler, L Briker, P Turko, G Karsai, N Zila, ...
Cancer Research 83 (7), 1128-1146, 2023
112023
Separating host and microbiome contributions to drug pharmacokinetics and toxicity. Science 363: eaat9931
M Zimmermann, M Zimmermann-Kogadeeva, R Wegmann, AL Goodman
92019
Targeting tumour-intrinsic neural vulnerabilities of glioblastoma
S Lee, T Weiss, M Bühler, J Mena, Z Lottenbach, R Wegmann, M Bihl, ...
bioRxiv, 2022.10. 07.511321, 2022
22022
Epithelial-mesenchymal transition is the main driver of intrinsic metabolism in cancer cell lines
S Cherkaoui, S Durot, J Bradley, S Critchlow, S Dubuis, MM Masiero, ...
bioRxiv, 2021.11. 02.466992, 2021
12021
The cellular hierarchy of acute myeloid leukemia informs personalized treatment
Y Severin, Y Festl, TM Benoit, R Wegmann, BD Hale, M Roiss, ...
medRxiv, 2024.07. 24.24310768, 2024
2024
SINGLE-CELL FUNCTIONAL TISSUE PROFILING IDENTIFIES PROMISING CANDIDATES FOR DRUG REPURPOSING AGAINST GLIOBLASTOMA
T Weiss, S Lee, M Buehler, J Mena, Z Lottenbach, R Wegmann, M Bihl, ...
NEURO-ONCOLOGY 25, 2023
2023
Functional and molecular tumor profiling for precision oncology
R Wegmann
ETH Zurich, 2023
2023
Long-term history dependence of growth rates of E. coli after nutrient shifts
D Christodoulou, A Mukherjee, R Wegmann, A Pagano, V Sharma, ...
bioRxiv, 2023
2023
ROS induction as a strategy to target persister cancer cells with low metabolic activity in NRAS mutated melanoma
OM Eichhoff, CI Stoffel, J Käsler, L Briker, P Turko, G Karsai, N Zila, ...
bioRxiv, 2022.10. 19.512839, 2022
2022
ROS induction as a strategy to target persister cancer cell metabolism
O Eichhoff, C Stoffel, L Briker, P Turko, G Karsai, V Paulitschke, ...
European Journal of Cancer 174, S3, 2022
2022
Image-based functional precision medicine for repurposing neuroactive drugs in glioblastoma
S Lee, T Weiss, M Bühler, R Wegmann, J Mena, M Bihl, S Goetze, ...
Cancer Research 82 (12_Supplement), 5325-5325, 2022
2022
P856: A SINGLE-CELL FUNCTIONAL PRECISION MEDICINE LANDSCAPE OF MULTIPLE MYELOMA
K Kropivsek, P Kachel, S Goetze, R Wegmann, Y Severin, BD Hale, ...
HemaSphere 6, 749-750, 2022
2022
S134: INTRA-PATIENT FUNCTIONAL HETEROGENEITY OF AML DETERMINES FIRST-LINE TREATMENT RESPONSE
Y Severin, Y Festl, M Roiss, T Benoit, T Heinemann, R Wegmann, ...
HemaSphere 6, 35-36, 2022
2022
Uncovering new therapeutic opportunities for glioblastoma by image-based ex vivo drug-screening
S Lee, T Weiss, M Buehler, R Wegmann, J Mena, M Bihl, S Goetze, ...
Brain Tumor Research and Treatment 10 (Suppl), 2022
2022
系统目前无法执行此操作,请稍后再试。
文章 1–20